Barclays
AKBA icon

Barclays’s Akebia Therapeutics AKBA Stock Holding History

Barclays’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,400
Closed -$79K – 5516
2020
Q1 		$79K Buy
10,400
+10,200
+5,100% +$79.4K ﹤0.01% 4945
2019
Q4 		$1K Hold
200
– – ﹤0.01% 6263
2019
Q3 		$1K Buy
+200
New +$857 ﹤0.01% 6568
2019
Q1 		– Sell
-4,811
Closed -$27K – 6976
2018
Q4 		$27K Buy
+4,811
New +$37.6K ﹤0.01% 5766

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barclays's AKBA Position: Q2 2026 in Review

Barclays reduced its Akebia Therapeutics (AKBA) stake by 9.7% in Q2 2026, selling an estimated $16.5K and leaving 128,358 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #3878.

Barclays first reported a position in AKBA in Q2 2014 and has held it in 42 quarters since. The position peaked at $3.58M in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Barclays held 128,358 shares of Akebia Therapeutics worth $146K as of Q2 2026.
  • Barclays sold 13,834 Akebia Therapeutics shares in Q2 2026, an estimated $16.5K.
  • Akebia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3878 holding.
  • Barclays first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 42 quarters since.
  • Barclays's Akebia Therapeutics position peaked at $3.58M in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.